巨头赛诺菲:Dupilumab业绩高涨94%;过专利药物迎来黄昏
2023-08-03 20:00
举报
Dupixent(IL-4R a)业绩为16.34亿欧元,同比大增93.8%;Praluent(PCSK9)业绩仅为1.46亿欧元,同比增长18%;波立维Plavix业绩为5....
相关阅读
2021-12-01
2023-09-05
2021-12-04
2021-12-07
2023-07-09
2023-02-15
2022-07-21
2023-08-21
2021-12-13
2021-11-27
2021-12-04
